Carl Zeiss Meditec AG (CZMWF)

OTCMKTS · Delayed Price · Currency is USD
34.66
0.00 (0.00%)
At close: Feb 10, 2026
Market Cap2.82B -46.0%
Revenue (ttm)2.61B +7.8%
Net Income165.68M -21.0%
EPS1.89 -19.8%
Shares Outn/a
PE Ratio17.00
Forward PE15.86
Dividend0.65 (2.07%)
Ex-Dividend DateMar 27, 2025
Volume77
Average Volume146
Open35.36
Previous Closen/a
Day's Range34.66 - 35.36
52-Week Range31.34 - 70.88
Beta1.44
RSI34.66
Earnings DateFeb 12, 2026

About Carl Zeiss Meditec AG

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and p... [Read more]

Sector Healthcare
Founded 1846
Employees 5,784
Stock Exchange OTCMKTS
Ticker Symbol CZMWF
Full Company Profile

Financial Performance

In fiscal year 2025, Carl Zeiss Meditec AG's revenue was 2.23 billion, an increase of 7.82% compared to the previous year's 2.07 billion. Earnings were 141.21 million, a decrease of -20.99%.

Financial numbers in EUR Financial Statements

News

Carl Zeiss Meditec Preliminary Q1 Operating Profit Declines; To Refine FY Guidance

(RTTNews) - Carl Zeiss Meditec AG (AFX.DE) reported that, in the first 3 months of fiscal 2025/26, the company recorded preliminary revenue of 467 million euros compared to 490 million euros, prior ye...

20 days ago - Nasdaq

Carl Zeiss Meditec: Why This Company Is A Good Choice For 2026

Carl Zeiss Meditec is rated a 'Strong Buy' with higher share price target, reflecting significant undervaluation and robust fundamentals. The company achieved over €2.2B in revenue (+7.5% YoY), strong...

27 days ago - Seeking Alpha

Invesco Global Opportunities Fund Q3 2025 Performance Review

Invesco Global Opportunities Fund outperformed most in consumer staples due to stock selection and in real estate due to an underweight allocation. Stock selection in consumer discretionary, IT and ma...

5 weeks ago - Seeking Alpha

Carl Zeiss Meditec AG (CZMWF) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Carl Zeiss Meditec AG (CZMWF) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Margin Pressures

2 months ago - GuruFocus

Q4 2025 Carl Zeiss Meditec AG Earnings Call Transcript

Q4 2025 Carl Zeiss Meditec AG Earnings Call Transcript

2 months ago - GuruFocus

Carl Zeiss Meditec AG (CZMWY) Q4 2025 Earnings Call Transcript

Carl Zeiss Meditec AG (CZMWY) Q4 2025 Earnings Call December 11, 2025 4:00 AM ESTCompany ParticipantsSebastian Frericks - Director of Investor...

2 months ago - Seeking Alpha

Carl Zeiss Meditec AG 2025 Q4 - Results - Earnings Call Presentation

2025-12-11. The following slide deck was published by Carl Zeiss Meditec AG in conjunction with their 2025 Q4 earnings call.

2 months ago - Seeking Alpha

Invesco International Small-Mid Company Fund Q3 2025 Top Contributors And Detractors

Invesco International Small-Mid Company Fund outperformed most in the real estate and consumer staples sectors due to stock selection. The fund's underweight in real estate also added to relative retu...

3 months ago - Seeking Alpha

Carl Zeiss Meditec: An Odd Reaction To 9M 2025 Earnings

Carl Zeiss Meditec is significantly undervalued after 9M25 results, with market overreaction creating a compelling entry point. See why CZMWF stock is a buy.

5 months ago - Seeking Alpha

Carl Zeiss: The Results After 6M25 Are Encouraging For 2025-2027E

Carl Zeiss Meditec remains a high-quality medtech leader with strong moats in ophthalmic and microsurgery. Read why CZMWF stock is a Buy.

8 months ago - Seeking Alpha

Carl Zeiss Meditec: Recovery Seems Clear Enough

Carl Zeiss Meditec remains a "Buy" despite tariff concerns, with a revised price target of €110/share, reflecting geopolitical uncertainties and potential impacts on US-based revenues. The company sho...

1 year ago - Seeking Alpha

Q1 2025 Carl Zeiss Meditec AG Earnings Call Transcript

Q1 2025 Carl Zeiss Meditec AG Earnings Call Transcript

1 year ago - GuruFocus

Carl Zeiss: Why I Am So Positive

Carl Zeiss Meditec is a high-quality MedTech company with a strong market position, low debt, and significant long-term upside potential despite current macroeconomic challenges. The company's fundame...

1 year ago - Seeking Alpha

My 3 Favorite European Stocks To Diversify Your Portfolio

Here is an emphasis on the importance of diversification in US-based investment portfolios to mitigate risks and enhance returns. The recommendation is to focus on sectors with strong growth potential...

1 year ago - Seeking Alpha

Carl Zeiss: Significant Underperformance, Valuation At Multi-Year Lows

Carl Zeiss Meditec has seen a 30%+ decline due to earnings and margin drops, but remains a strong market leader with significant long-term upside. Despite current underperformance, the company's strat...

1 year ago - Seeking Alpha

Carl Zeiss Meditec AG (CZMWF) Q3 2024 Earnings Call Transcript

Carl Zeiss Meditec AG (OTCPK:CZMWF) Q3 2024 Results Conference Call August 6, 2024 4:30 AM ET Company Participants Sebastian Frericks - Director of Investor Relations Markus Weber - CEO & Chairman of ...

1 year ago - Seeking Alpha

Carl Zeiss Meditec: Slightly Better Valuation, Still A Significant Upside

Carl Zeiss Meditec has underperformed in the medtech field, but its long-term appeal remains intact. The company reported a decline in revenue and margins in the first half of 2023/2024, mainly due to...

1 year ago - Seeking Alpha

Carl Zeiss Meditec AG (CZMWF) Q2 2024 Earnings Call Transcript

Carl Zeiss Meditec AG (OTCPK:CZMWF) Q2 2024 Earnings Conference Call May 8, 2024 4:30 AM ET Company Participants Sebastian Frericks - Head, IR Markus Weber - CEO Justus Wehmer - CFO Conference Call Pa...

1 year ago - Seeking Alpha

Carl Zeiss Meditec AG Completes Acquisition of Dutch Ophthalmic Research Center (D.O.R.C.); Companies Unite to Shape Ophthalmology Market

ZEISS secures regulatory approvals to acquire D.O.R.C.; companies now shift focus to integration implementation, fueling world-class innovation, and driving market expansion strategy for ophthalmic me...

2 years ago - PRNewsWire

Carl Zeiss: We've Seen Outperformance, But I See More Upside Potential

Carl Zeiss Meditec has seen a significant increase in stock performance, up over 29% in less than 3 months. The company has shown strong top-line growth but a decline in EBIT and EBIT margin. Challeng...

2 years ago - Seeking Alpha

Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.)

Acquisition will extend the company's leadership in ophthalmic medical devices market and expands its position in the vitreo-retinal surgery segment JENA, Germany , Dec. 15, 2023 /PRNewswire/ -- Carl ...

2 years ago - PRNewsWire